Irritable bowel syndrome – a literature review
DOI:
https://doi.org/10.12775/JEHS.2023.13.04.005Keywords
irritable bowel syndrome, pathogenesis, diagnosis, treatmentAbstract
Introduction: Irritable bowel syndrome (IBS) is one of the most common diseases affecting people around the world. It is characterized by irregular bowel movements and abdominal pain. IBS significantly reduces the quality of life of patients. Despite such a frequent occurrence of this disease, its correct diagnosis and treatment still causes many problems for primary care physicians. Aim of the study: The aim of the study is to present the current state of knowledge on the pathophysiology, diagnostics and drugs used in irritable bowel syndrome. Description of the state of knowledge: Many factors may play a role in the pathogenesis of IBS. The most common are: genetic factors, intestinal motility disorders, visceral hypersensitivity, mental disorders, especially disorders of the brain-gut axis regulation, past intestinal infections, intestinal microbiota disorders and food intolerances. The Rome IV criteria are currently used in the diagnosis of IBS. Treatment of irritable bowel syndrome includes lifestyle modification and dietary management, pharmacotherapy and psychotherapy.
Summary: Irritable bowel syndrome is a chronic disease, symptoms often recur and complete recovery is not possible.
References
Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut. 1986;27:37–40. doi: 10.1136/gut.27.1.37.
Colucci R, Gambaccini D, Ghisu N, Rossi G, Costa F, Tuccori M, De Bortoli N, Fornai M, Antonioli L, Ricchiuti A, et al. Influence of the serotonin transporter 5HTTLPR polymorphism on symptom severity in irritable bowel syndrome. PLoS One. 2013;8:e54831. doi: 10.1371/journal.pone.0054831.
Lekha S. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014 Jun 14;20(22):6759-73. doi: 10.3748/wjg.v20.i22.6759.
Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015 Mar 3;313(9):949-58. doi: 10.1001/jama.2015.0954.
Bengtson MB, Rønning T, Vatn MH, Harris JR. Irritable bowel syndrome in twins: genes and environment. Gut. 2006;55:1754–1759. doi: 10.1136/gut.2006.097287.
Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol 2005;100(6):1340-4.
Bellini M, Gambaccini D, Stasi C, Urbano MT, Marchi S, Usai-Satta P. Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol 2014;20(27):8807-20. doi: 10.3748/wjg.v20.i27.8807.
Soares RLS. Irritable bowel syndrome: A clinical review. World J Gastroenterol. 2014 Sep 14; 20(34): 12144–12160. doi: 10.3748/wjg.v20.i34.12144.
Radovanovic-Dinic B,Tesic-Rajkovic S, Grgov S.,Petrovic G, Zivkovic V. Irritable bowel syndrome - from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Mar;162(1):1-9. doi: 10.5507/bp.2017.057. Epub 2018 Jan 18.
Faure C, Patey N, Gauthier C, Brooks EM, Mawe GM. Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients. Gastroenterology. 2010;139:249–258. doi: 10.1053/j.gastro.2010.03.032.
Valdez-Morales EE, Overington J, Guerrero-Alba R, Ochoa-Cortes F, Ibeakanma CO, Spreadbury I, Bunnett NW, Beyak M, Vanner SJ. Sensitization of peripheral sensory nerves by mediators from colonic biopsies of diarrhea-predominant irritable bowel syndrome patients: a role for PAR2. Am J Gastroenterol. 2013;108:1634–1643. doi: 10.1038/ajg.2013.241.
Nozu T, Kudaira M, Kitamori S, Uehara A. Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol 2006;41(3):217-22. doi: 10.1007/s00535-005-1748-z.
Dinan TG, Quigley EM, Ahmed SM, Scully P, O’Brien S, O’Mahony L, O’Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130:304–311. doi: 10.1053/j.gastro.2005.11.033.
Mertz H. Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gut. 2002;51 Suppl 1:i29–i33. doi: 10.1136/gut.51.suppl_1.i29.
Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19;S0016-5085(16)00223-7. doi: 10.1053/j.gastro.2016.02.032.
Bartnik W, Chojnacki J, Paradowski L. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterol Klin. 2009; 1(1): 9–17
Moayyedi P, Mearin F, Azpiroz F, et al. Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterology Journal. 2017;5(6):773-788. doi:10.1177/2050640617731968.
Lewis SJ, Heaton KW. Stool Form Scale as a Useful Guide to Intestinal Transit Time, Scandinavian Journal of Gastroenterology, 32:9, 920-924. DOI: 10.3109/00365529709011203.
Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, Rydzewska G. Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik. Prz Gastroenterol. 2018;13(4):259-288. doi: 10.5114/pg.2018.78343. Epub 2018 Sep 19. PMID: 30581501; PMCID: PMC6300851.
Levy R, Linde J, Feld K. The association of gastrointestinal symptoms with weight, diet and exercise in weight-loos program participants. Clin Gastroenterol Hepatol. 2005;10:992–6.
Zijdenbos I, de Wit N, van der Heijden G. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev. 2009;21:CD006442.
Manheimer E, Wieland L, Cheng K, et al. Acupuncture for irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:835–48.
Schnabel L, Buscail C, Sabate J, et al. Association between ultra-processed food consumption and functional gastrointestinal disorders: results from the French NutriNet-Santé Cohort. Am J Gastroenterol. 2018;113:1217–28.
Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012 Aug;142(8):1510-8. doi: 10.3945/jn.112.159285. Epub 2012 Jun 27. PMID: 22739368.
Shahbazkhani B, Sadeghi A, Malekzadeh R, Khatavi F, Etemadi M, Kalantri E, Rostami-Nejad M, Rostami K. Non-Celiac Gluten Sensitivity Has Narrowed the Spectrum of Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial. Nutrients. 2015 Jun 5;7(6):4542-54. doi: 10.3390/nu7064542. PMID: 26056920; PMCID: PMC4488801.
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009 Aug 27;339:b3154. doi: 10.1136/bmj.b3154. PMID: 19713235; PMCID: PMC3272664.
Daley AJ, Grimmett C, Roberts L, Wilson S, Fatek M, Roalfe A, Singh S. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int J Sports Med. 2008 Sep;29(9):778-82. doi: 10.1055/s-2008-1038600. Epub 2008 May 6. PMID: 18461499.
Ghadir MR, Habibinejad H, Heidari A, Vahedi H. Doxepin is more effective than nortriptyline and placebo for the treatment of diarrhea-predominant irritable bowel syndrome: a randomized triple-blind placebo-controlled trial. Tehran University Medical Journal. 2011;69(6):352-358. Accessed January 19, 2023.
Bianchi M, Festa V, Moretti A, Ciaco A, Mangone M, Tornatore V, Dezi A, Luchetti R, De Pascalis B, Papi C, Koch M. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Aliment Pharmacol Ther. 2011 Apr;33(8):902-10. doi: 10.1111/j.1365-2036.2011.04606.x. Epub 2011 Mar 2. PMID: 21366632.
Acosta A, Camilleri M, Shin A, Linker Nord S, O'Neill J, Gray AV, Lueke AJ, Donato LJ, Burton DD, Szarka LA, Zinsmeister AR, Golden PL, Fodor A. Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2016 May 26;7(5):e173. doi: 10.1038/ctg.2016.32. PMID: 27228404; PMCID: PMC4893683.
Awad RA, Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Dis. 2010 Nov;12(11):1131-8. doi: 10.1111/j.1463-1318.2009.01990.x. PMID: 19575740.
Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77-80. doi: 10.3109/00365528709091003. PMID: 3306903.
Johnston JM, Kurtz CB, Macdougall JE, Lavins BJ, Currie MG, Fitch DA, O'Dea C, Baird M, Lembo AJ. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010 Dec;139(6):1877-1886.e2. doi: 10.1053/j.gastro.2010.08.041. Epub 2010 Aug 27. PMID: 20801122.
Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009 Feb 1;29(3):329-41. doi: 10.1111/j.1365-2036.2008.03881.x. Epub 2008 Nov 4. PMID: 19006537.
Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9. PMID: 23583433.
Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther. 2004 Feb 1;19(3):271-9. doi: 10.1111/j.1365-2036.2004.01859.x. PMID: 14984373.
Sallon S, Ben-Arye E, Davidson R, Shapiro H, Ginsberg G, Ligumsky M. A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula. Digestion. 2002;65(3):161-71. doi: 10.1159/000064936. PMID: 12138321.
Krueger D, Gruber L, Buhner S, Zeller F, Langer R, Seidl S, Michel K, Schemann M. The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine. Neurogastroenterol Motil. 2009 Nov;21(11):1203-e110. doi: 10.1111/j.1365-2982.2008.01242.x. Epub 2009 Jan 30. PMID: 19210628.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Iwona Cuber, Artur Aghadi, Edyta Białowąs, Ewelina Dybała, Magdalena Mazurek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1673
Number of citations: 0
